Tag: autoantibody

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025.

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsAutoantibody

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

BlockchainCloudMining Launches XRP-Powered Cloud Mining Contracts Offering Daily Profits

Ex-CIA Insider Points to Overlooked U.S. Resource as Possible Gamechanger in Trump’s Economic Agenda

Tag: autoantibody

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us